Jul. 8 at 6:18 AM
$ALDX Aldeyra's board can strongly argue that the FDA review division committed an administrative contradiction. By sending draft labels, the FDA implicitly acknowledged the drug was ready for the public, only to abruptly change their minds at the finish line without providing a concrete scientific reason. Now that Aldeyra has the full context of the March 2026 Complete Response Letter (CRL), they are presenting highly refined arguments that could cause the FDA to yield.
Worst case, they go to FDRR, because FDA didn't want any new trials.
The minutes can be published anytime now and if it's positive, we can see stock going back to new highs. I'm here to hold shares until the minutes released
